Why a Few Patents Could Decide the Future of Fast-Onset Weed Drinks

October 23, 2026

Photo via Pexels.

Walk into any dispensary in Michigan or California right now and you'll find a cooler full of five-milligram seltzers promising onset in fifteen to thirty minutes instead of the ninety-to-two-hour wait for an edible to clear the liver. That's not a marginal tweak -- it's the format most people building the next phase of the cannabis consumer base are betting on, because it finally mimics the cadence of a happy hour beer or a glass of wine with dinner. You crack it open, you feel something reasonably quickly, you can titrate a second one if the first wasn't enough. Alcohol companies spent a century training consumers on that rhythm, and cannabis beverages are the first format with a real shot at borrowing it wholesale.

Here's the part that doesn't get discussed enough outside formulation circles: the thing holding fast-onset beverages back isn't the chemistry, and it isn't regulatory uncertainty, though both of those are real factors. It's that an enormous share of the products sitting on shelves trace their emulsion technology back through licensing agreements to a single company. SoRSE Technology, based in Seattle and originally founded in 2016 as Tarukino Holdings by Howard Lee, didn't build itself into a beverage manufacturer -- it built itself into something closer to a toll booth, licensing water-soluble cannabinoid emulsion technology to dozens of brands rather than competing with them directly. That's a specific, unusual business model for this industry, and it raises a question worth sitting with: is this IP gatekeeping actually throttling innovation and keeping prices artificially high, or is it just the normal, slightly uncomfortable pattern that every consumer-tech category goes through on its way to maturity -- the way chipmakers, flavor houses, and generic drug manufacturers all eventually settled into licensing ecosystems built around a handful of patent holders?

What Fast-Onset Actually Requires, Chemically

Photo by olia danilevich via Pexels.

Start with the basic chemistry problem, because it explains everything downstream. THC and most other cannabinoids are lipophilic -- they dissolve readily in fat and oil but barely at all in water. Pour cannabis oil into a can of sparkling water and you get an oily film on top, not a beverage. To make a drinkable product that stays uniformly mixed and doesn't separate on a store shelf for six months, manufacturers need to emulsify the cannabinoid oil, breaking it into droplets small enough to stay suspended in liquid rather than floating free. That's the whole function of the nanoemulsion and liposomal technology at the center of this industry.

Droplet size matters for more than shelf stability, though. Generally speaking, smaller droplets present more surface area relative to volume, which means faster passage through the gut lining and into the bloodstream. That's the entire value proposition of a fast-onset beverage versus a standard edible: a gummy has to survive digestion and first-pass metabolism through the liver, a process that typically takes ninety minutes to two hours and converts a meaningful share of THC into 11-hydroxy-THC, a more sedating metabolite. A well-formulated nano-emulsified beverage can shortcut a chunk of that timeline, with some products advertising onset in fifteen to thirty minutes.

None of this is new science, and that's the important part. Liposomal and emulsion-based delivery systems have been standard tools in pharmaceuticals and food science for decades -- liposomal vitamin C supplements, injectable liposomal drugs like certain chemotherapy formulations, and emulsified flavor and nutrient systems in packaged food have all relied on the same underlying principle of suspending a lipophilic compound in an aqueous medium. What's genuinely novel in the current wave of cannabis beverage patents isn't the mechanism -- it's the specific formulation ratios, surfactant choices, and stability profiles tuned for cannabinoids at beverage-relevant concentrations and shelf lives.

That distinction matters legally. Because nobody can patent emulsification itself -- it's decades-old, well-documented public knowledge -- companies are left patenting narrow, specific methods and formulations instead. That's exactly why the cannabis beverage patent landscape looks the way it does today: not one dominant, industry-blocking patent, but a fragmented thicket of overlapping narrow claims, each covering a particular ratio, process step, or stabilizer combination.

SoRSE's Licensing Model: One Gatekeeper, 40+ Brands

Photo by geralt via Pixabay.

Into that fragmented landscape, one company has built something closer to a monopoly on practical access, if not on the underlying science. SoRSE Technology, founded in Seattle in 2016 under the name Tarukino Holdings by Howard Lee, has positioned itself as a dominant licensor of water-soluble cannabinoid emulsion technology. The company doesn't primarily manufacture and sell its own finished beverages at scale -- it licenses its emulsion platform to other companies who build and sell the actual products. By SoRSE's own account, it now licenses to more than 40 brands across multiple countries, including recognizable names like Mad Tasty and APRCH.

That number is worth sitting with. Most of the fast-onset beverage brands a consumer sees in a dispensary cooler or, increasingly, in hemp-derived form on a convenience store shelf, are not running their own proprietary emulsion R&D program. They're renting someone else's. That's a meaningfully different competitive structure than, say, the vape hardware market, where dozens of companies genuinely compete on independently developed heating and airflow technology.

The clearest proof of how valuable that licensing position has become is the deal SoRSE struck with Valens GroWorks: a five-year exclusive license covering Canada, Europe, Australia, and Mexico, closed at a reported $10 million USD, split between $6 million in cash and $4 million in Valens stock. Structuring a licensing deal with equity attached signals that both sides expect this technology access to be worth more over time, not less -- Valens wasn't just buying a formula, it was buying exclusivity across entire national markets.

What's notable is the method SoRSE has used to build this position. It's licensing-as-leverage, not litigation-as-leverage. Unlike patent holders in other industries who've built their power by suing competitors into submission or into settlement, SoRSE hasn't needed an aggressive courtroom strategy, because exclusive territorial licensing deals accomplish the same goal more quietly -- locking up entire regions and distribution relationships before a competitor even has standing to challenge anything. The practical upshot for a new beverage brand entering this space is blunt: your time-to-market and your margin structure will often depend less on your own formulation talent and more on which licensing relationship you can secure, and on what terms.

The Patent-Pending Paradox

Photo via Pexels.

If you assumed the core emulsion patents filed years ago would be aging out and opening the field up, SoRSE's recent filing activity complicates that story. The company filed a patent application for a Method for preparing stable liquid emulsion forms of plant extract on November 20, 2023, with the patent granted February 17, 2026. That's a company still actively expanding its intellectual property position on technology whose fundamental mechanism -- emulsification -- is conceptually decades old and sitting in food science textbooks.

Here's the part that catches people off guard: SoRSE's own public-facing FAQ materials have continued to describe its technology as patent-pending even in periods when the company holds issued, granted patents. That's not necessarily a contradiction so much as a signal of strategy -- it points toward a layered, continuation-style filing approach, where new applications building on or narrowing earlier claims are kept moving through the patent review pipeline more or less continuously, so there's always something pending even as earlier filings resolve into issued patents.

This is a recognizable playbook from other industries, most famously pharmaceuticals. Insulin manufacturers have used so-called patent thickets -- layered, incremental reformulation patents covering delivery devices, concentration levels, and minor molecular tweaks -- to extend effective market exclusivity on older insulin formulations for decades beyond what a single 20-year patent term would suggest. The individual patents aren't necessarily illegitimate, but the cumulative effect is a moving target that's expensive and risky for a competitor to fully map before deciding whether they're clear to operate.

That ambiguity itself functions as a deterrent for cannabis beverage formulators. A brand deciding whether to build proprietary emulsion technology in-house or simply license SoRSE's platform has to weigh the cost of a license against the legal risk of accidentally infringing a claim buried somewhere in a continuation filing they haven't tracked closely. For most companies without a dedicated IP litigation budget, paying the licensing fee is simply the cheaper, lower-risk choice -- even if, in principle, a sufficiently well-resourced competitor might be able to design around the specific claims.

It's worth being precise about what this argument is and isn't. This is a reasoned inference about incentive structures, not an accusation that SoRSE is acting in bad faith. Continuation filing is a completely legal, widely used strategy across chemical, pharmaceutical, and food science patenting. But whether or not it's intentional strategy versus simply diligent IP management, the market effect lands the same way either way: competitors and new entrants stay cautious, and caution has a price.

A Crowded, Overlapping Claims Landscape

SoRSE isn't operating in a vacuum, and that matters for how this plays out. US Patent 10,738,268 B2, held by Leo, claims nanoemulsion methods specifically tied to beverage serving sizes and sweetener formulations -- a narrow slice of the same underlying problem, filed by a different party entirely. International filing WO2020081550A1 and its US counterpart US20210361574A1 claim nanoemulsion methods explicitly framed around achieving quicker onset times, again covering ground conceptually adjacent to SoRSE's claims but filed independently. Multiple companies, in other words, are patenting narrow slices of the same basic idea at roughly the same time.

That fragmentation -- not one company holding a single blocking patent -- is arguably the more accurate description of what's actually slowing adoption. A formulator trying to launch a new fast-onset beverage doesn't face one clear licensing decision. They face a minefield of overlapping, narrow claims from several different patent holders, each covering a different combination of droplet size, surfactant ratio, or serving format, with no single entity able to grant a clean, comprehensive license that removes all risk.

There's a real historical parallel here, and it's the early smartphone patent wars of the 2010s. Apple, Samsung, Nokia, and a handful of others held overlapping patents on touchscreen gestures, slide-to-unlock mechanisms, and radio protocols -- no single company had a patent that blocked the entire market, but the dense web of overlapping narrow claims still slowed new entrants, raised legal costs industry-wide, and shaped which companies could afford to compete at all. Smaller players without deep legal budgets found it safer to license broadly or avoid certain features entirely rather than risk litigation.

But there's a genuine counter-case worth taking seriously, and it cuts against the doom-and-gloom read. Overlapping patents held by competing companies also mean no single company controls pricing outright. Valens, SoRSE, and a growing number of smaller independent emulsion formulators are all competing for the same pool of beverage brands looking to license technology. Over time, that competitive pressure among licensors -- rather than regulatory intervention or patent expiration -- is plausibly what pushes licensing costs down, the same way competition among chipset suppliers eventually commoditized smartphone component pricing even while patent disputes continued in parallel.

What Happens to Adoption If the Chokepoint Loosens -- or Tightens

Advanced delivery methods dramatically speed up cannabis beverage onset times—liposomal and nanoemulsion formulations act within 10-15 minutes, compared to 60-90 minutes for standard beverages and edibles.

Project this forward one to three years and a few plausible scenarios emerge, each resting on a different historical analogy. The optimistic case follows the generic drug playbook: as SoRSE's older foundational claims age toward their natural expiration and newer continuation patents face the kind of scrutiny and design-around efforts that eventually erode pharma patent thickets, expect more independent formulators to enter the beverage emulsion space. Generic drug manufacturers have followed exactly this pattern for decades, waiting out patent cliffs before flooding a market with lower-cost alternatives once the legal risk drops.

If licensing costs do fall as a result, the more interesting downstream effect is where these beverages show up. Right now, fast-onset cannabis drinks remain largely a premium dispensary category. If formulation licensing gets cheaper and more competitive, expect these products to migrate into more price-competitive, mainstream retail channels -- a path that closely mirrors what happened with CBD products, which moved from boutique wellness shops into major chain drugstore shelves within a few years once formulation and extraction costs fell industry-wide.

The conservative counter-case deserves equal weight, though. Patent continuation strategies, as the insulin example shows, can extend effective exclusivity well past a nominal 20-year patent term on narrow technical grounds -- a modified ratio here, a new stabilizer there, each restarting part of the clock. If SoRSE and its competitors continue layering continuation filings the way pharmaceutical companies have, the licensing chokepoint could persist considerably longer than this near-term horizon suggests, regardless of how old the foundational chemistry is.

Regulatory uncertainty adds another variable entirely separate from the patents themselves. The 2018 Farm Bill's hemp provisions already created a confusing split between hemp-derived and marijuana-derived THC beverages, each regulated differently depending on the state. If federal legalization or new hemp-derived THC beverage rules shift which state and federal bodies have enforcement authority, that could change who even has standing to assert these patent claims in the first place, and against whom.

Finally, watch for consolidation as a release valve. If licensing costs stay stubbornly high, expect beverage brands to increasingly acquire small emulsion-tech companies outright rather than pay ongoing licensing fees -- a pattern that mirrors how larger consumer packaged goods companies acquired flavor-tech and food-science startups throughout the 2010s rather than licensing their technology indefinitely.

Strip away the marketing language about bioavailability and rapid onset, and the honest state of fast-onset cannabis beverages in 2024 looks like this: the chemistry works, it's been understood for decades, and it isn't the bottleneck. The bottleneck is who controls access to a workable, shelf-stable version of that chemistry, and what they charge for it. SoRSE's licensing empire, the Valens deal's eight-figure price tag, and the steady drip of continuation filings all point to an industry where the real competitive battlefield is legal and contractual, not laboratory-based.

For anyone trying to actually track where this category is headed, that means watching patent expiration dates and new patent filings with the same attention you'd give state cannabis legislation. In this particular corner of the industry, a grant date or an expiration date functions almost like a regulatory deadline -- it reshapes who can enter the market and at what cost, in ways that are just as consequential as a new state law but far less visible to anyone outside formulation and legal circles.

The brands most likely to come out ahead over the next three years probably won't be the ones with the cleverest in-house formulation team. They'll be the ones that correctly bet on which licensing relationship to build around, which legal gray area was worth operating in, and when to switch horses as the patent landscape shifts underneath them. That's a strange thing to say about a product category built on something as simple as a flavored seltzer, but it's the honest read of where the leverage actually sits right now.